Venture Houston 2018
Skip Content

12 March 2018

Prevail completes $75m series A process

Neurodegenerative disease startup Prevail Therapeutics has raised series A funding from backers including Alexandria Venture Investments.

Author: Robert Lavine, News Editor

US-based gene therapy developer Prevail Therapeutics has secured $75m in a series A round featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate trust Alexandria Real Estate Equities.